{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Pancreatic+Ductal+Adenocarcinoma&page=2", "query": { "condition": "Metastatic Pancreatic Ductal Adenocarcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Pancreatic+Ductal+Adenocarcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T03:12:42.541Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07076121", "title": "A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "BMS-986504", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2025-10-23", "completion_date": "2029-05-03", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-05-22T03:12:42.541Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Springdale, Arkansas + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07076121" }, { "nct_id": "NCT02754726", "title": "Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Untreated Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Albumin-bound paclitaxel", "type": "DRUG" }, { "name": "Paricalcitol", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HonorHealth Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2016-04", "completion_date": "2024-03-22", "has_results": true, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-05-22T03:12:42.541Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02754726" }, { "nct_id": "NCT05630183", "title": "A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Botensilimab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2023-03-27", "completion_date": "2025-12-05", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-05-22T03:12:42.541Z", "location_count": 36, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 28 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT05630183" }, { "nct_id": "NCT00096083", "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "isolated perfusion", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delcath Systems Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 56, "start_date": "2004-09", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2013-10-23", "last_synced_at": "2026-05-22T03:12:42.541Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096083" }, { "nct_id": "NCT05462717", "title": "Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Pancreatic Ductal Adenocarcinoma", "Advanced Solid Tumor" ], "interventions": [ { "name": "RMC-6291", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2022-09-19", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-05-22T03:12:42.541Z", "location_count": 15, "location_summary": "Springdale, Arkansas • Orange, California • Sacramento, California + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462717" }, { "nct_id": "NCT05440942", "title": "Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Trametinib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Peter Hosein, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2023-01-19", "completion_date": "2025-05-30", "has_results": false, "last_update_posted_date": "2025-06-05", "last_synced_at": "2026-05-22T03:12:42.541Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05440942" }, { "nct_id": "NCT01040000", "title": "QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "NPC-1C/NEO-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Precision Biologics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 94, "start_date": "2012-01", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2017-08-04", "last_synced_at": "2026-05-22T03:12:42.541Z", "location_count": 6, "location_summary": "Tampa, Florida • Baltimore, Maryland • St Louis, Missouri + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01040000" }, { "nct_id": "NCT06040541", "title": "Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Advanced Solid Tumors" ], "interventions": [ { "name": "RMC-9805", "type": "DRUG" }, { "name": "RMC-6236", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 604, "start_date": "2023-09-07", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-05-22T03:12:42.541Z", "location_count": 17, "location_summary": "Sacramento, California • New Haven, Connecticut • Sarasota, Florida + 12 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06040541" }, { "nct_id": "NCT02558894", "title": "Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "MEDI4736 monotherapy", "type": "DRUG" }, { "name": "tremelimumab+MEDI4736", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-11-16", "completion_date": "2017-06-15", "has_results": true, "last_update_posted_date": "2018-08-02", "last_synced_at": "2026-05-22T03:12:42.541Z", "location_count": 2, "location_summary": "Tampa, Florida • New York, New York", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02558894" }, { "nct_id": "NCT05074472", "title": "A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Pancreatic Ductal; Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Biliary Cancer Metastatic", "Ovarian Serous Cystadenocarcinoma" ], "interventions": [ { "name": "ZB131", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ZielBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2022-01-14", "completion_date": "2023-09-30", "has_results": false, "last_update_posted_date": "2024-01-29", "last_synced_at": "2026-05-22T03:12:42.541Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05074472" } ] }